Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-REZ 2005 for relapsed or refractory pediatric embryonal brain tumors and ependymoma
2005-002618-40Phase 2Completed
- Sponsor
- University of Bonn
- Start
- Jan 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of etoposide, carboplatin, temozolomide, thiotepa and trofosfamide in medulloblastoma, primitive neuroectodermal tumor (PNET) and ependymoma (2 arms), sponsored by University of Bonn. Primary endpoints: Progression-free survival from start of therapy and Overall survival from start of therapy. Started Jan 2006; status: completed.
02
Drugs
etoposidecarboplatintemozolomidethiotepatrofosfamide
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)ependymoma
Beyond the preview
Go deeper on 2005-002618-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002618-40.